Clinical Trials Browser

NIH × Interventional × cediranib × Clear all

NCT01064648 2026-03-18

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Phase 1/2 Active not recruiting

117 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT01364051 2026-03-18

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Phase 1 Active not recruiting

Melanoma

NCT02893917 2026-03-18

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Phase 2 Active not recruiting

90 enrolled 19 charts

Prostatic Neoplasms

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Phase 1/2 Active not recruiting

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT02345265 2026-03-05

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Phase 2 Active not recruiting

70 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Phase 2/3 Active not recruiting

582 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Phase 2 Completed

34 enrolled 22 charts

Sarcoma, Alveolar Soft Part

NCT02484404 2025-11-25

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Phase 1/2 Active not recruiting

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00942877 2025-03-03

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Phase 2 Completed

53 enrolled 17 charts

Sarcoma, Sarcoma, Alveolar Soft Part

NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

NCT00662506 2023-06-06

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Completed

Glioblastoma, Gliosarcoma

NCT01062425 2022-07-26

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2 Completed

261 enrolled 10 charts

Glioblastoma, Gliosarcoma

NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Phase 1/2 Completed

127 enrolled 18 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT00321581 2019-11-21

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

Phase 1 Completed

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT01132820 2019-08-08

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Phase 2 Completed

53 enrolled 11 charts

Endometrial Adenocarcinoma

NCT00278343 2018-08-29

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Phase 2 Completed

74 enrolled 11 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00243061 2018-08-27

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Phase 2 Completed

24 enrolled 12 charts

Uveal Melanoma, Melanoma

NCT00527124 2018-08-09

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Terminated

57 enrolled 12 charts

Prostatic Neoplasms

NCT01260688 2018-08-08

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Phase 2 Completed

22 enrolled 23 charts

Prostatic Neoplasms

NCT00410904 2018-04-13

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

Phase 2 Completed

60 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT00326872 2017-08-18

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Phase 2 Terminated

26 enrolled 8 charts

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT01229111 2017-03-29

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Phase 2 Terminated

14 enrolled 11 charts

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT00475150 2017-02-15

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2 Completed

39 enrolled 9 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT00427973 2016-10-31

AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

Phase 2 Terminated

17 enrolled 7 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT00326664 2016-03-07

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Phase 1 Completed

Familial ependymoma, Astrocytoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms, Rhabdoid Tumor, Optic Nerve Glioma

NCT00227760 2016-02-29

Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Phase 2 Completed

44 enrolled 8 charts

Carcinoma, Renal Cell

NCT00244881 2015-12-07

A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

Phase 2 Completed

26 enrolled 9 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00458978 2015-05-05

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

Phase 2 Completed

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT00979862 2015-04-15

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01131234 2014-12-23

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Ependymoma, Glioblastoma, Glioma, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Gliosarcoma, Breast Neoplasms, Male

NCT00245063 2014-10-02

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

Phase 2 Completed

25 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung

NCT00303862 2014-05-21

AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

Phase 2 Terminated

10 enrolled 5 charts

Carcinoma, Renal Cell

NCT00458731 2014-02-19

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Phase 1 Completed

LymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

NCT01229930 2013-08-26

Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

Uterine Cervical Neoplasms

NCT00305656 2013-08-22

AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 2 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00238394 2013-06-05

Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT00937482 2013-03-08

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Phase 1 Terminated

BreastCNSDermatologicGastrointestinalGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Melanoma, Rectal Neoplasms, Breast Neoplasms, Male

NCT00321724 2013-01-15

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell